Beijing SL Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 002038.SZ

Beijing SL Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2023: USD 143.44 M

Beijing SL Pharmaceutical Co., Ltd. Revenue is USD 143.44 M for the year ending December 31, 2023, a -5.75% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
  • Beijing SL Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2022 was USD 152.18 M, a -20.40% change year over year.
  • Beijing SL Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2021 was USD 191.19 M, a 12.15% change year over year.
  • Beijing SL Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2020 was USD 170.47 M, a -41.51% change year over year.
  • Beijing SL Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2019 was USD 291.47 M, a -7.52% change year over year.
Key data
Date Revenue Gross Profit Operating Income EBIT
Market news
Loading...
Shenzhen Stock Exchange: 002038.SZ

Beijing SL Pharmaceutical Co., Ltd.

CEO Dr. Mingbo Xu Ph.D.
IPO Date Sept. 9, 2004
Location China
Headquarters Building 1, Bitongyuan
Employees 856
Sector Health Care
Industries
Description

Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, researches, develops, produces, and markets genetic engineering and related drugs in the People's Republic of China and internationally. The company's finished formulations includes temozolomide; arsenic trioxide; lenalidomide; docetaxel; paclitaxel; filgrastim Recombinant human granulocyte colony-stimulating factor; recombinant human interleukin-11; recombinant human interleukin-2; thymopentin; vinorelbine bitartrate; hydroxyl-camptothecine; nimustine hydrochloride; asparaginase; PEG L-asparaginase; calcium foliate; recombinant human basic fibroblast growth factor; ciclosporin; mycophenolate mofetil dispersible; ornidazole; adefovir dipivoxil; levofloxacin hydrochloride; azithromycin; ribavirin; tenofovir disoproxil fumarate; valacylovir hydrochloride; lysozyme; stavudine; tropisetron hydrochloride; granisetron hydrochloride; omeprazole; ademetionine 1,4-butanedisulfonate; glutathione; enoxaparin sodium; coenzyme complex; ginkgo biloba extract; simvastatin; telmisartan; naftopidil; nicergoline; zaleplon; cytidine disodium triphosphate; febuxostat; risedronate sodium; loratadine dispersible; somatostatin; octreotide acetate; calcitonin (salmon); paracetamol and tramadol hydrochloride; and etodolac. It also offers active pharmaceutical ingredients. The company was formerly known as Beijing BaiLuyuan Bio-Pharmaceutical Co., Ltd and changed its name to Beijing SL Pharmaceutical Co., Ltd. in 1998. Beijing SL Pharmaceutical Co., Ltd. was founded in 1994 and is based in Beijing, the People's Republic of China.

Similar companies

002019.SZ

Yifan Pharmaceutical Co., Ltd.

USD 1.43

2.16%

002030.SZ

Daan Gene Co., Ltd.

USD 0.79

3.04%

000963.SZ

Huadong Medicine Co., Ltd

USD 4.53

2.64%

002001.SZ

Zhejiang NHU Company Ltd.

USD 2.97

0.01%

002007.SZ

Hualan Biological Engineering Inc.

USD 2.17

2.25%

StockViz Staff

January 15, 2025

Any question? Send us an email